A series of dice with a bag on them illustrating cost cuts
Biotech

Cellectis will shed 70% of workforce as part of in vivo pivot

Cellectis’ pivot from allogeneic CAR-Ts to in vivo therapies is set to come at the expense of 70% of its workforce.
James Waldron Nov 13, 2026 9:18am
akt health

Why scientific progress depends on knowing when to look again

Brought to you by Ipsen
Stock market IPO share price

Sanofi-backed Windward hits $225M IPO, as Rezera delays listing

Nov 13, 2026 7:10am
Advanced Analytics Help Reduce Control Animal Use While Preserving Scientific Rigor

How Virtual Control Groups Are Shaping Safety Studies

Brought to you by Charles River Laboratories
Regeneron

Regeneron posts positive ph. 2 POTS data, eyes pivotal trial

Nov 13, 2026 3:31am
Charles River booth at AACR 2026

Charles River pays $470M for 2 Frontage labs in Pennsylvania

Nov 13, 2026 11:00am
More News

The promise of molecular gates and what comes next

Nov 13, 2026 9:58am

Rezolute gets an uplift from ph. 3 win ahead of FDA meet

Nov 13, 2026 9:30am

Researchers identify protein panel to improve ALS detection

Nov 13, 2026 9:00am

BMS unites R&D as chief of research departs—Chutes & Ladders

Nov 13, 2026 8:30am